FTC, FDA Take Closer Look at Disclosures
The Federal Trade Commission is cracking down on companies with questionable advertising disclosures. The Food and Drug Administration, meanwhile, may allow shorter lists of side effects in drug and medical device ads, even as it prepares tougher standards for how these companies use online advertising and social media. The focus ...
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
Drug, Device Companies Face New FDA Electronic Submissions
The Food and Drug Administration is overhauling how it accepts submissions for a host of filing requirements imposed on drug and medical device makers. For many, this will be the first time the submissions have ever been filed electronically. While the move away from paper documents may ultimately be advantageous ...
-
ArticleFTC’s two commissioners vote to order Walmart to pay $100M to settle gig driver allegations
Walmart has agreed to pay $100 million to settle allegations that it deceived delivery drivers about their pay and tips, the Federal Trade Commission announced.
-
OpinionHow to responsibly roll out AI in compliance, from a former Google exec
Compliance officers across the economy are being told to adopt AI - to save costs, increase and expand compliance coverage through more real-time and contextualized information, navigate the ever-changing regulatory landscape, and leverage more analytical firepower to make better decisions.